Model: ksg-dfci/TrialSpace-1225
Author: ksg-dfci
Pipeline: sentence-similarity
Library: sentence-transformers
Tags: sentence-transformers, safetensors, qwen3, sentence-similarity, feature-extraction, dense, generated_from_trainer, loss:MultipleNegativesRankingLoss, loss:OnlineContrastiveLoss, arxiv:1908.10084, arxiv:1705.00652, endpoints_compatible, region:us
Card metadata: tags: sentence-transformers, sentence-similarity, feature-extraction, dense, generated_from_trainer, loss:MultipleNegativesRankingLoss, loss:OnlineContrastiveLoss
widget: source_sentence: Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age: 5  
Sex: Male  
Cancer type: Medulloblastoma  
Primary site: Cerebellum (posterior fossa)  
Histology: WHO Grade IV, Group 4 embryonal tumor (small round blue cell)  

Current extent: Localized persistent residual disease confined to the posterior fossa (vermian nodule ~1.5 cm plus several <3 mm cerebellar cortical foci); no leptomeningeal, spinal, or distant metastases on latest MRI (11/2024); disease considered stable.  

Biomarkers:   
• YAP1 positive, β‑catenin negative (consistent with Group 4)  
• Ki‑67 proliferation index ≈60 % on repeat biopsy (↑ from 40 % at diagnosis)  
• Chromosome 17q gain (+3 copies) – present at diagnosis and retained  
• CDK6 amplification, OTX2 amplification, TERT promoter −124 C>T mutation – present at diagnosis and retained  
• KMT2C frameshift, low‑level MYCN gain – present at diagnosis  
• Acquired homozygous CDKN2A deletion (loss of CDK inhibitor) – identified on recurrence NGS (8/2022)  
• SMARCA4 p.Glu1579Lys missense mutation – acquired on recurrence NGS (8/2022)  
• No MYC, TP53, CTNNB1 mutations; no actionable target per current FDA‑approved pediatric drugs.  

Treatment history:  
# 12/2020 – 12/2020: Gross‑total resection of right cerebellar/brainstem medulloblastoma via right suboccipital/craniotomy; margins negative.  
# 8/2022 (≈age 3.1 yr): Oral prednisone 1 mg/kg twice daily × 14 days for peritumoral edema associated with recurrence.  
# 8/2022 – present: Low‑dose dexamethasone (range 0.05–0.15 mg/kg daily) continuously for symptom control (edema, nausea, ataxia). No systemic chemotherapy, no craniospinal irradiation, and no enrolment in a clinical trial yet (investigation pending).
sentences: Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age range allowed: 1 Year to 39 Years. Sex allowed: Male and Female. Cancer type allowed: Myeloid sarcoma. Histology allowed: Extramedullary presentation of myeloid malignancy. Cancer burden allowed: Relapsed or refractory disease. Prior treatment required: Full recovery from prior hematopoietic stem cell transplantation or anthracycline exposure. Prior treatment excluded: Current administration of anticancer agents (except intrathecal agents or hydroxyurea). Biomarkers required: NA. Biomarkers excluded: Philadelphia chromosome/BCR‑ABL1 fusion, KMT2A rearrangement, acute promyelocytic leukemia characteristics, Down‑syndrome‑associated leukemia., Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age range allowed: ≥ 36 months and < 22 years. Sex allowed: Both. Cancer type allowed: Primary malignant cerebellar brain tumor – Giant cell glioblastoma. Histology allowed: Giant cell glioblastoma. Cancer burden allowed: Single cerebellar lesion measurable 1.0–3.0 cm, surgially accessible, recurrent or progressive after standard therapy, not diffuse across ≥3 brain lobes, not involving ventricles or brainstem. Prior treatment required: Surgical resection and/or radiotherapy and/or systemic chemotherapy. Prior treatment excluded: NA. Biomarkers required: NA. Biomarkers excluded: NA., Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age range allowed: ≥ 36 months and < 22 years. Sex allowed: Both. Cancer type allowed: Primary malignant cerebellar brain tumor – Giant cell glioblastoma. Histology allowed: Giant cell glioblastoma. Cancer burden allowed: Single cerebellar lesion measurable 1.0–3.0 cm, surgially accessible, recurrent or progressive after standard therapy, not diffuse across ≥3 brain lobes, not involving ventricles or brainstem. Prior treatment required: Surgical resection and/or radiotherapy and/or systemic chemotherapy. Prior treatment excluded: NA. Biomarkers required: NA. Biomarkers excluded: NA., source_sentence: Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age: 73  
Sex: Male  
Cancer type: Non‑small cell lung cancer (lung adenocarcinoma)  
Histology: Moderately differentiated adenocarcinoma, lepidic and acinar pattern  
Current extent: Metastatic (stage IV) with progressive thoracic disease (enlarging right‑upper‑lobe mass and new left‑lower‑lobe nodules), stable adrenal metastases, known osseous metastases, and treated intracranial metastases (post‑stereotactic radiosurgery)  

Biomarkers:  
• PD‑L1 Tumor Proportion Score 60 % (high expresser)  
• MET exon 14 skipping mutation (activating)  
• EGFR wild‑type, KRAS wild‑type, ALK/ROS1/RET negative  
• STK11 p.F354L (missense, likely pathogenic)  
• TP53 p.Y220C (missense, likely pathogenic)  
• CDKN2A homozygous deletion (loss of function)  
• ERBB2 amplification (copy ≈ 6.2)  
• FGFR2 amplification (copy ≈ 5.8)  
• MYC gain (copy ≈ 4.5)  
• BRAF p.G469A (missense, likely pathogenic)  
• PIK3CA p.E545K (missense, likely pathogenic)  
• Microsatellite stable, Tumor Mutational Burden 4.3 mut/Mb (low)  

Treatment history:  
# 12/27/2010 – early 2012: Front‑line pembrolizumab 200 mg IV q3 weeks + carboplatin AUC 5 IV d1 + pemetrexed 500 mg/m² IV d1 + bevacizumab 15 mg/kg IV d1 (every 21 days). Achieved partial response (≈29 % decrease in primary tumor) and maintained stable extracranial disease until development of Grade 3 immune‑related pneumonitis after Cycle 2 (early 2012). Pembrolizumab permanently discontinued; chemotherapy withheld after initial cycles.  

# Early 2012 – mid 2012: High‑dose glucocorticoids (methylprednisolone 2 mg/kg daily → oral prednisone taper over 8 weeks) for Grade 3 pneumonitis; tapered to maintenance prednisone 10 mg PO daily, completed August 2012.  

# 07/23/2012 – 10/23/2012: Second‑line docetaxel 75 mg/m² IV q21 days (total 6 cycles). Growth‑factor support with pegfilgrastim for Grade 2 neutropenia. Extrathoracic disease remained stable; however, new sub‑centimetric intracranial lesions appeared, prompting stereotactic radiosurgery (SRS) in late 2012.  

# 02/09/2013 onward: No further systemic antitumor therapy recorded. Disease progression evidenced by increase of right‑upper‑lobe mass to 5.0 cm and emergence of new left‑lower‑lobe nodules (RECIST progressive disease).
sentences: Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age range allowed: 1 Year to 39 Years. Sex allowed: Male and Female. Cancer type allowed: Mixed phenotype acute leukemia, T‑myeloid. Histology allowed: T‑myeloid mixed phenotype acute leukemia. Cancer burden allowed: Relapsed or refractory disease. Prior treatment required: Full recovery from prior hematopoietic stem cell transplantation or anthracycline exposure. Prior treatment excluded: Current administration of anticancer agents (except intrathecal agents or hydroxyurea). Biomarkers required: NA. Biomarkers excluded: KMT2A rearrangement, Philadelphia chromosome/BCR‑ABL1 fusion., Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age range allowed: 0 through 45 years. Sex allowed: both sexes. Cancer type allowed: acute lymphoblastic leukaemia. Histology allowed: B‑cell precursor acute lymphoblastic leukaemia. Cancer burden allowed: newly diagnosed, never relapsed, de novo disease. Prior treatment required: NA. Prior treatment excluded: systemic corticosteroids ≥10 mg/m²/day prednisone equivalents for longer than one week before diagnosis; any chemotherapeutic agent administered within four weeks before diagnosis. Biomarkers required: surface immunoglobulin negative phenotype; IG::MYC rearrangement accepted only when BCL2 and BCL6 rearrangements are absent. Biomarkers excluded: KMT2A‑rearranged B‑cell precursor ALL in patients younger than 1 year; Philadelphia chromosome‑positive (t[9;22]/BCR‑ABL) ALL; surface immunoglobulin positive B‑ALL (mature B‑ALL); coexistence of IG::MYC rearrangement with BCL2 or BCL6 rearrangement; known hereditary ALL‑prone syndromes (except Down syndrome)., Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age range allowed: 18-75 years. Sex allowed: Male and Female. Cancer type allowed: Any malignant solid tumor. Histology allowed: NA. Cancer burden allowed: Disease of any stage in patients who refuse or are intolerant of standard therapy and whose tumor shows programmed death ligand 1 (PD‑L1) expression TPS ≥ 1 %. Prior treatment required: Refusal of or intolerance to standard recommended therapy. Prior treatment excluded: NA. Biomarkers required: PD‑L1 TPS ≥ 1 % measured by IHC 22C3; presence of at least one positively expressed tumor neoantigen. Biomarkers excluded: NA., source_sentence: Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age: 67  
Sex: Male  

Cancer type: Prostate adenocarcinoma  
Histology: Acinar adenocarcinoma, Gleason 3 + 3 = 6 (Grade Group 1)  
Current extent: No evidence of disease (biochemically controlled, PSA ≤ 0.6 ng/mL)  
Biomarkers: Gleason score 6; PSA trends documented (5.2 → 2.1 → 1.0 → 0.8 → 0.6 ng/mL)  
Treatment history:  
# 2018‑09‑01 (?) – 2019‑03‑??: Definitive external‑beam radiation therapy, total dose 78 Gy in 39 fractions to prostate (curative intent) – achieved biochemical response with PSA nadir 0.8 ng/mL; no recurrence on serial follow‑up  

---

Cancer type: Breast carcinoma (male) presenting as Paget disease of the right nipple‑areolar complex, underlying invasive ductal carcinoma  
Histology: Invasive ductal carcinoma, HER2‑positive (IHC 3⁺, FISH amplification average copy ≈ 18, NGS copy ≈ 15), estrogen‑receptor negative, progesterone‑receptor negative  
Current extent: Metastatic (Stage IV) – pulmonary nodules, pleural effusions, extensive osteolytic/osteoblastic bone metastases (ribs, vertebrae, pelvis, left femur)  
Biomarkers: HER2 amplification (IHC 3⁺, FISH CN ≈ 18, NGS CN ≈ 15); ER < 1 %; PR < 1 %; TMB 4 mut/Mb (low); microsatellite stable; co‑occurring AKT1 p.E17K, PIK3CA p.E545K, TP53 p.Y220C, CDKN2A deletion  
Treatment history:  
# 2020‑10‑11 – 2022‑04‑08: First‑line trastuzumab (loading 8 mg/kg then 6 mg/kg q3 wk) + pertuzumab (loading 840 mg then 420 mg q3 wk) + carboplatin (AUC 5 iv q3 wk) – administered continuously from age 62; 5 cycles recorded by Oct 2020; produced partial response (≈30 % reduction of pulmonary nodules, stable bone disease) and grade 2 chemotherapy‑related anemia (required one RBC transfusion, subsequently resolved)  
# 2021‑10‑11 – 2022‑04‑08: Palliative external‑beam radiation therapy to left proximal femur, 30 Gy in 10 fractions (delivered at age 65) – resulted in marked pain improvement and radiographic sclerosis indicating local control  
# 2022‑06‑07 – present: Second‑line trastuzumab‑deruxtecan (Herceptin‑Deruxtecan) initiated at age 66; after three cycles developed grade 2 drug‑induced interstitial lung disease (ILD) → treatment held, oral prednisone 40 mg tapered over 6 weeks; HRCT at age 67 confirmed complete resolution; therapy restarted at 75 % dose thereafter and continues (response: further ≥20 % reduction of all measurable pulmonary nodules, stable bone disease)  
# Throughout 2020‑2022: Monthly zoledronic acid infusions for bone protection; antihypertonic medication for hypertension; anticholinergic (oxybuta­n/ trospium) for grade 2 urinary frequency related to prior prostate irradiation; analgesics (acetaminophen, ibuprofen, short‑acting oxycodone) for bone pain; routine cardiac monitoring (echocardiogram EF 55 %) owing to prolonged dual HER2 blockade
sentences: Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age range allowed: 18-75 years. Sex allowed: Male and Female. Cancer type allowed: Any solid tumor. Histology allowed: Any histologic subtype. Cancer burden allowed: Metastatic disease or locally recurrent disease. Prior treatment required: Failure of prior standard anti‑tumor therapy (chemotherapy, radiotherapy, targeted therapy, immunotherapy, or biologic therapy). Prior treatment excluded: Receipt of any prior cell therapy product. Biomarkers required: HPV18 positive and HLA‑DRB1*0901 positive. Biomarkers excluded: NA., Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age range allowed: 0 to 29 years. Sex allowed: both. Cancer type allowed: B‑cell acute lymphoblastic leukemia. Histology allowed: B‑lymphoblast precursor acute lymphoblastic leukemia. Cancer burden allowed: NA. Prior treatment required: NA. Prior treatment excluded: NA. Biomarkers required: CD19 surface expression and hypodiploid karyotype (fewer than 45 chromosomes). Biomarkers excluded: NA., Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age range allowed: 18-75 years. Sex allowed: Male and Female. Cancer type allowed: Any malignant solid tumor. Histology allowed: NA. Cancer burden allowed: Stage IIIB‑IV disease that has progressed after prior standard therapy and for whom immune‐monotherapy is planned, regardless of PD‑L1 result. Prior treatment required: Progression after receipt of standard therapy. Prior treatment excluded: NA. Biomarkers required: Presence of at least one positively expressed tumor neoantigen; PD‑L1 testing permitted but not mandatory. Biomarkers excluded: NA., source_sentence: Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age: 30  
Sex: Female  

Cancer type: Breast cancer (left side)  
Histology: Invasive ductal carcinoma, grade 3, triple‑negative (ER‑, PR‑, HER2‑)  
Current extent: Metastatic, bone‑predominant disease (multiple osseous lesions, no visceral metastases)  

Biomarkers:  
- Ki‑67 ≈ 80 % (initial core) / ≈ 68 % (residual surgical specimen)  
- PD‑L1 tumor proportion score 20 % (spike assay)  
- Germline BRCA2 c.5946delT pathogenic truncating mutation  
- Somatic TP53 p.R273H missense mutation (hotspot)  
- PALB2 copy‑number loss (complete deletion)  
- Tumor mutational burden 15 mut/Mb (intermediate‑high)  
- Microsatellite stable  

Treatment history:  
# 2019‑09 ~ 2020‑01: Neoadjuvant dose‑dense AC (doxorubicin 60 mg/m² + cyclophosphamide 600 mg/m² q14 days, 6 cycles) – completed without major adverse events.  
# 2020‑01 ~ 2020‑04: Weekly paclitaxel 80 mg/m² (12 weeks) – completed; tolerated Grade 2 alopecia, intermittent nausea.  
# 2020‑05‑08: Breast‑conserving surgery (wide local excision) with sentinel lymph node biopsy (1/3 nodes macro‑positive). Margins negative, ypT1a N1 M0.  
# 2020‑06 ~ 2020‑08 (approx.): Adjuvant whole‑breast radiation, 50 Gy + boost – completed.  
# 2020‑10‑24 ~ 2020‑12‑05: Front‑line metastatic therapy – pembrolizumab 200 mg IV q3 wk + nab‑paclitaxel 100 mg/m² d1,8,15 q28 d. Best response: mixed bone response; Grade 2 immune‑related thyroiditis treated with levothyroxine 75 μg daily; Grade 3 transaminitis emerged. Therapy stopped 2020‑12‑05 due to progression and toxicity.  
# 2020‑12‑05 ~ 2021‑02‑xx: Second‑line metastatic therapy – carboplatin AUC 5 IV d1 q21 d + etoposide 100 mg/m² d1‑3 q21 d. Administered two cycles; complicated by Grade 3 neutropenia with febrile episode; therapy held upon discovery of pregnancy (≈8 weeks gestation) in February 2021.  
# 2021‑02‑xx ~ 2021‑05‑xx: No systemic anti‑cancer therapy during pregnancy (first trimester through delivery). Supportive care only.  
# Early 2021 (prior to delivery): Palliative radiation – single‑fraction 8 Gy external beam to L3 vertebral compression fracture (pain relief). Planned second 8 Gy session to right iliac crest (scheduled March 2021).  
# 2021‑06‑18 present: Post‑delivery systemic therapy – olaparib 300 mg orally twice daily initiated (BRCA2‑directed PARP inhibition). Concurrent supportive measures: denosumab 120 mg SC q4 weeks (planned) and continued analgesia.
sentences: Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age range allowed: ≥18 years. Sex allowed: All. Cancer type allowed: non‑small cell lung cancer. Histology allowed: Any non‑small cell lung cancer histology. Cancer burden allowed: Advanced (stage IIIB not amenable to definitive chemoradiotherapy or stage IIIC) or metastatic (stage IV) disease with at least one radiographically measurable lesion. Prior treatment required: Receipt of appropriate first‑line standard‑of‑care systemic therapy for advanced/metastatic non‑small cell lung cancer that includes a platinum doublet chemotherapy (unless medically contraindicated). Prior treatment excluded: NA. Biomarkers required: Available tumor tissue for evaluation of MUC16 expression by immunohistochemistry (testing to be done during screening). Biomarkers excluded: NA., Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age range allowed: 18-75 years. Sex allowed: Male and Female. Cancer type allowed: Any malignant solid tumor. Histology allowed: NA. Cancer burden allowed: Advanced or metastatic disease that has progressed after standard therapy (failure or intolerance). Prior treatment required: Failure or intolerance of standard approved therapy for the tumor. Prior treatment excluded: NA. Biomarkers required: Presence of at least one positively expressed tumor neoantigen identified on tumor tissue; optional assessment of PD‑L1 tumor proportion score (TPS) not required. Biomarkers excluded: NA., Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age range allowed: 1 Year to 39 Years. Sex allowed: Male and Female. Cancer type allowed: T‑cell acute lymphoblastic leukemia. Histology allowed: T‑cell acute lymphoblastic lymphoma/leukemia. Cancer burden allowed: Relapsed or refractory disease. Prior treatment required: Full recovery from prior hematopoietic stem cell transplantation or anthracycline exposure. Prior treatment excluded: Current administration of anticancer agents (except intrathecal agents or hydroxyurea). Biomarkers required: NA. Biomarkers excluded: Philadelphia chromosome/BCR‑ABL1 fusion., source_sentence: Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age: 63  
Sex: Male  
Cancer type: Diffuse large B‑cell lymphoma (DLBCL)  
Histology: Activated B‑cell (non‑germinal‑center) phenotype, CD20 positive, MUM1 positive, BCL2 positive, Ki‑67≈95 %  
Current extent: Limited residual disease – residual metabolic activity in the original right posterior thigh soft‑tissue mass (partial metabolic response) and a solitary right iliac lymph node with stable low‑volume uptake (stable disease); no other sites of disease evident.  

Biomarkers:  
- Immunohistochemistry: CD20+, MUM1+, BCL2+, CD10‑, BCL6‑, Ki‑67≈95%  
- FISH: No MYC, BCL2, or BCL6 rearrangements (triple‑hit excluded)  
- NGS (original thigh lesion): MYD88 L265P (VAF ≈35 %), CD79B Y196F (VAF ≈30 %), CARD11 S328F (VAF ≈28 %), REL copy‑number gain (≈3–4 copies) – low tumor mutational burden (5 mut/Mb), microsatellite stable.  
- Additional alterations identified in iliac node (September 2013): TP53 p.R248Q (VAF ≈22 %), CDKN2A homozygous deletion.  

Treatment history:  
# Early 2011–mid 2011: R‑CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) – 6 cycles, 21‑day schedule. Best response: partial metabolic response (Deauville 4).  
# Mid 2011 (following R‑CHOP): High‑dose BEAM conditioning with autologous stem‑cell transplantation – achieved only persistent residual disease (no complete remission).  
# Early 2012 (exact infusion date unspecified, Day 0 of CAR‑T): Axicabtagene ciloleucel (axi‑cel) CAR‑T after fludarabine/cyclophosphamide lymphodepletion. Course complicated by Grade 3 cytokine‑release syndrome (tocilizumab, brief vasopressors) and Grade 2 immune effector cell‑associated neurotoxicity syndrome (resolved). Day 60 restaging (July 2012) showed partial metabolic response of thigh lesion (↓SUV from ≈13 to 4.2) but emergence of a new right iliac node (SUV ≈9.3) consistent with progressive disease.  
# Late 2012 (December 2012): Palliative external‑beam radiation to right iliac node, 30 Gy in 15 fractions (2 Gy per fraction). Resulted in symptom relief and reduction of nodal size/metabolic activity (node size ↓ to 2.5 cm, SUV ≈5.8).  
# 2013 March onward: Observation/off‑therapy; serial imaging through 2014 demonstrates stable disease (persistent low‑grade uptake in thigh lesion, SUV ≈4.2; iliac node stable, SUV ≈5.8). No further systemic therapy administered.
sentences: Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age range allowed: 18-75 years. Sex allowed: Male and Female. Cancer type allowed: Any malignant solid tumor. Histology allowed: NA. Cancer burden allowed: Stage IIIB‑IV disease that has progressed after prior standard therapy and for whom immune‐monotherapy is planned, regardless of PD‑L1 result. Prior treatment required: Progression after receipt of standard therapy. Prior treatment excluded: NA. Biomarkers required: Presence of at least one positively expressed tumor neoantigen; PD‑L1 testing permitted but not mandatory. Biomarkers excluded: NA., Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age range allowed: ≥18 years. Sex allowed: both. Cancer type allowed: diffuse large b cell lymphoma. Histology allowed: diffuse large b cell lymphoma–not otherwise specified. Cancer burden allowed: evaluable/measurable disease; absent massive uncontrolled pleural, pericardial, or peritoneal effusions, pulmonary lymphangitis, and liver involvement exceeding 50 %. Prior treatment required: relapsed or refractory disease after prior systemic anti‑lymphoma therapy (including patients ineligible for car t‑cell therapy). Prior treatment excluded: any concurrent antitumor‑directed drug therapy. Biomarkers required: NA. Biomarkers excluded: NA., Instruct: Given a cancer patient summary, retrieve clinical trial options that are reasonable for that patient; or, given a clinical trial option, retrieve cancer patients who are reasonable candidates for that trial. Age range allowed: >=18. Sex allowed: female. Cancer type allowed: ovarian carcinosarcoma. Histology allowed: mixed carcinoma. Cancer burden allowed: relapsed or refractory disease after at least one prior platinum‑based regimen (platinum‑resistant <183 days) with measurable disease. Prior treatment required: at least one prior line of platinum chemotherapy. Prior treatment excluded: prior MUC1‑directed therapy. Biomarkers required: MUC1 expression positive (>0 IHC) assessed at screening. Biomarkers excluded: NA
pipeline_tag: sentence-similarity
library_name: sentence-transformers
Likes: 0 | All-time downloads: 735
Created: 2025-09-03 14:01:48